House FDA Hearing: No Plan for Domestic Drug Manufacturing
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.